Article
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
BMC research notes - 26 Nov 2013
Rossing Henrik H, Grauslund Morten, Urbanska Edyta M, Melchior Linea C, Rask Charlotte K, Costa Junia C, Skov Birgit G, Sørensen Jens Benn, Santoni-Rugiu Eric
Abstract excerpt
BACKGROUND: Anaplastic lymphoma kinase-positive non-small cell lung carcinoma patients are generally highly responsive to the dual anaplastic lymphoma kinase and MET tyrosine kinase inhibitor crizotinib. However, they eventually acquire resistance to this drug, preventing the anaplastic lymphoma kinase inhibitors from having a prolonged beneficial effect. The molecular mechanisms responsible for crizotinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.